Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.56 |
| ▸ | HTR2A | P28223 | 4/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31381402 | 0.93 | CYP3A4 (0.60) | ADRA2CSLC6A4HTR2ASLC6A2HTR2B | |
| SCHEMBL26668483 | 0.93 | CYP3A4 (0.60) | ADRA2CSLC6A4HTR2ASLC6A2HTR2B | |
| SCHEMBL26668476 | 0.93 | CYP3A4 (0.60) | ADRA2CSLC6A4HTR2ASLC6A2HTR2B | |
| SCHEMBL17277433 | 0.86 | SLC6A4 (0.56) | ADRA2CSLC6A4HTR2ASLC6A2HTR2B | |
| SCHEMBL8925989 | 0.86 | ADRA2C (0.66) | ADRA2CSLC6A4HTR2ASLC6A2HTR2B | |
| SCHEMBL8925985 | 0.86 | ADRA2C (0.66) | ADRA2CSLC6A4HTR2ASLC6A2HTR2B | |
| SCHEMBL12075467 | 0.84 | SLC6A4 (0.57) | ADRA2CSLC6A4HTR2ASLC6A2HTR2B | |
| SCHEMBL3162540 | 0.84 | HTR2A (0.53) | ADRA2CSLC6A4HTR2ASLC6A2HTR2B | |
| SCHEMBL21254308 | 0.84 | SLC6A4 (0.53) | ADRA2CSLC6A4HTR2ASLC6A2HTR2B | |
| SCHEMBL9814604 | 0.84 | SLC6A4 (0.53) | ADRA2CSLC6A4HTR2ASLC6A2HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078098-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | SUPERNUS PHARMACEUTICALS, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4493550-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | Supernus Pharmaceuticals, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-118451064-A | Process for preparing derivatives of substituted morpholines | 苏佩努斯制药公司 | 2024-08-06 | — | — | CN | disclosed |
| US-11964951-B2 | Process of making derivatives of substituted morpholines | SUPERNUS PHARMACEUTICALS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230357173-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | SUPERNUS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230295100-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | SUPERNUS PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023177845-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | SUPERNUS PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20220024885-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | SUPERNUS PHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20190300492-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | SUPERNUS PHARMACEUTICALS, INC. (US) | 2019-10-03 | — | — | US | disclosed |
| US-10160733-B2 | Methods for producing viloxazine salts and novel polymorphs thereof | SUPERNUS PHARMACEUTICALS, INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180265482-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | SUPERNUS PHARMACEUTICALS, INC. (US) | 2018-09-20 | — | — | US | disclosed |
| US-10005743-B2 | Methods for producing viloxazine salts and novel polymorphs thereof | SUPERNUS PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20160304475-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | SUPERNUS PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-9434703-B2 | Viloxazine compositions | SUPERNUS PHARMACEUTICALS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9403783-B2 | Methods for producing viloxazine salts and novel polymorphs thereof | SUPERNUS PHARMACEUTICALS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| EP-2558437-B1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | SUPERNUS PHARMACEUTICALS INC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150126735-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | SUPERNUS PHARMACEUTICALS INC. (US) | 2015-05-07 | — | — | US | disclosed |
| EP-2558437-A2 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | Supernus Pharmaceuticals, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011130194-A2 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | SUPERNUS PHARMACEUTICALS INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-20110251198-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | SUPERNUS PHARMACEUTICALS INC. (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005743-B2 | Methods for producing viloxazine salts and novel polymorphs thereof | CYP3A5, VIL1, CYP3A4 | ADRA2C 452/4885SLC6A4 229/4885HTR2A 86/4885 |
| US-20230295100-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | UGT2B7, CYP3A7, CYP3A4 | ADRA2C 319/4885SLC6A4 87/4885HTR2A 281/4885 |
| US-11964951-B2 | Process of making derivatives of substituted morpholines | UGT2B7, CYP3A7, CYP3A4 | ADRA2C 319/4885SLC6A4 87/4885HTR2A 281/4885 |
| US-20260078098-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | HTR2C, SLC6A2, HTR1D | ADRA2C 37/4885SLC6A4 14/4885HTR2A 21/4885 |
| US-10160733-B2 | Methods for producing viloxazine salts and novel polymorphs thereof | CYP3A5, VIL1, CYP3A4 | ADRA2C 452/4885SLC6A4 229/4885HTR2A 86/4885 |
| US-20160304475-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | CYP3A5, VIL1, CYP3A4 | ADRA2C 452/4885SLC6A4 229/4885HTR2A 86/4885 |
| US-20220024885-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | CYP3A5, VIL1, CYP3A4 | ADRA2C 452/4885SLC6A4 229/4885HTR2A 86/4885 |
| US-20180265482-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | CYP3A5, VIL1, CYP3A4 | ADRA2C 452/4885SLC6A4 229/4885HTR2A 86/4885 |
| US-20190300492-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | CYP3A5, VIL1, CYP3A4 | ADRA2C 452/4885SLC6A4 229/4885HTR2A 86/4885 |
| US-20230357173-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | UGT2B7, CYP3A7, CYP3A4 | ADRA2C 319/4885SLC6A4 87/4885HTR2A 281/4885 |
| US-20150126735-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | CYP3A5, VIL1, CYP3A4 | ADRA2C 452/4885SLC6A4 229/4885HTR2A 86/4885 |
| US-20110251198-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | CYP3A5, VIL1, CYP3A4 | ADRA2C 452/4885SLC6A4 229/4885HTR2A 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.